Short Interest in IceCure Medical Ltd (NASDAQ:ICCM) Decreases By 6.1%

IceCure Medical Ltd (NASDAQ:ICCM) saw a large decrease in short interest in the month of September. As of September 30th, there was short interest totalling 369,000 shares, a decrease of 6.1% from the September 15th total of 393,100 shares. Based on an average daily trading volume, of 579,100 shares, the short-interest ratio is presently 0.6 days. Currently, 1.5% of the company’s shares are short sold.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $2.50 target price on shares of IceCure Medical in a report on Thursday, September 12th.

Hedge Funds Weigh In On IceCure Medical

An institutional investor recently bought a new position in IceCure Medical stock. Renaissance Technologies LLC acquired a new position in IceCure Medical Ltd (NASDAQ:ICCM) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 66,400 shares of the company’s stock, valued at approximately $49,000. Renaissance Technologies LLC owned approximately 0.15% of IceCure Medical as of its most recent SEC filing. 0.62% of the stock is owned by institutional investors.

IceCure Medical Trading Down 6.8 %

Shares of ICCM traded down $0.04 during mid-day trading on Wednesday, reaching $0.54. 739,917 shares of the company’s stock traded hands, compared to its average volume of 509,851. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.97 and a quick ratio of 2.54. The stock’s 50-day moving average is $0.63 and its two-hundred day moving average is $0.84. IceCure Medical has a 12 month low of $0.48 and a 12 month high of $1.57. The stock has a market cap of $24.65 million, a P/E ratio of -1.76 and a beta of 0.56.

IceCure Medical (NASDAQ:ICCM) last issued its earnings results on Tuesday, August 20th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01. The firm had revenue of $1.01 million during the quarter, compared to analyst estimates of $0.90 million. IceCure Medical had a negative net margin of 410.22% and a negative return on equity of 111.27%. During the same period in the previous year, the firm earned ($0.09) earnings per share. Research analysts forecast that IceCure Medical will post -0.27 earnings per share for the current fiscal year.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.